Last reviewed · How we verify

NCT06557434

AV-23-001 AVAVA MIRIA Pilot Study

Active, enrolled NA Last updated 7 March 2025
What this trial tests

NA trial testing MIRIA in Wrinkle in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
6 November 2023
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorAVAVA, Inc.
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment200
Start date6 November 2023
Primary completion31 December 2026
Estimated completion31 December 2026
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

AVAVA, Inc.

Who can join

18 and older, any sex, with Wrinkle or Acne Scars - Mixed Atrophic and Hypertrophic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This non-significant risk study is intended to demonstrate the use of the MIRIA Skin Treatment System can show improvement in dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to, benign pigmented lesions, benign cutaneous lesions, wrinkles, textural irregularities, or scars). The study is also intended to assist in determination of the optimal laser configuration and treatment parameters that most consistently yield results.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Wrinkle

Currently open trials in the same condition.

Other AVAVA, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06557434.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing